Dr Jason Ezra Hawkes Addresses Immunotherapy Innovation, Uptake Issues in Atopic Dermatitis
October 6th 2022Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed recent advancements in immunotherapy for atopic dermatitis and what unmet needs persist to address uptake issues and patient-specific care needs.
Watch
Contributor: How to Fight the Cold and the Flu This Season
October 6th 2022With cold and flu season approaching, tips for avoiding the worst of the respiratory viruses are important for facing the coming months, when health experts expect an uptick in flu cases compared with the past 2 years.
Read More
Federal rules that take effect today will allow all patients full access to their health records in a digital format; 66 clinics nationwide have stopped providing abortions in the 100 days since the overturning of Roe v Wade; a Gallup poll found that more than half of Americans had a negative view of health care cost and equity.
Read More
Prior Authorization Can Work in MA but Not Without Changes, Researchers Say
October 6th 2022In a recent opinion published in JAMA, health policy researchers reviewed the advantages and disadvantages of prior authorization in Medicare Advantage (MA) to identify key areas that need improvement.
Read More
Medical and advocacy groups are petitioning the FDA to change the label for mifepristone to reduce barriers for miscarriage care; health insurers are becoming more flexible to ensure emergency care is met after Hurricane Ian; President Joe Biden will nominate US Surgeon General Vivek Murthy, MD, MBA, for the executive board of the World Health Organization (WHO).
Read More
Does Early Intervention Promote Favorable, Sustained Outcomes in Psoriasis?
October 5th 2022The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.
Read More
Dr Rona Silkiss Details the Use of Biologics to Treat Thyroid Eye Disease
October 4th 2022At the American Academy of Ophthalmology's annual conference, Rona Z. Silkiss, MD, FACS, an oculoplastic surgeon and owner of Silkiss Eye Surgery, dived into how biologic therapies can be used to treat thyroid eye disease and what can be done to ensure patients have access to these treatments.
Watch
Dr Michael Cohen Contrasts the Manifestation and Treatment of Wet vs Dry AMD
October 4th 2022Michael N. Cohen, MD, a retinal surgeon at Wills Eye Hospital and Mid Atlantic Retina, describes the differences between wet and dry age-related macular degeneration (AMD) and how gene therapy could help treat the condition in the future.
Watch
Optum and Change Healthcare have completed their merger initiated in 2021; efficacy of the Jynneos vaccine is in question after 90 of 7339 individuals contracted monkeypox after vaccination; the CDC will no longer maintain a list of country-by-country COVID-19 travel advisories.
Read More
Periostin as Biomarker May Be More Useful Than Eosinophils in ECRS
October 4th 2022Despite extensive study, eosinophilic chronic rhinosinusitis (ECRS) remains a significant health problem with few effective treatments, so this study compared periostin levels among those who did and did not have ECRS to assess its potential as a disease biomarker.
Read More
Medicare Part B Pricing Changes Aimed at Encouraging Biosimilar Use Begin
October 3rd 2022One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.
Read More
Community-Based Cycling Program Shows Positive Impact on Symptom Management in Parkinson Disease
October 3rd 2022Location, cost, and transportation were cited as important factors regarding adherence and satisfaction with community-based exercise programs among patients with Parkinson disease.
Read More
High-Dose, Extended Duration Aflibercept Injections Benefit Patients With DME, nAMD
October 3rd 2022Results from the pivotal PHOTON and PULSAR trials highlighted the success of 8-mg aflibercept every 12 or 16 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Read More